{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MM-121", "query": { "intervention": "MM-121" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=MM-121&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T02:17:54.333Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01447225", "title": "Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2011-10", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-09-14", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 4, "location_summary": "Lafayette, Indiana • Buffalo, New York • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Lafayette", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447225" }, { "nct_id": "NCT02538627", "title": "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "MM-151", "type": "DRUG" }, { "name": "MM-121", "type": "DRUG" }, { "name": "MM-141", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-08", "completion_date": "2016-10-05", "has_results": false, "last_update_posted_date": "2017-09-05", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 5, "location_summary": "Aurora, Colorado • Sandy Springs, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02538627" }, { "nct_id": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Squamous Cell Head and Neck Cancer", "Non-small Cell Lung Cancer", "Triple Negative Breast Cancer", "Other Tumors With EGFR Dependence" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2011-10", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01451632" }, { "nct_id": "NCT03241810", "title": "Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2017-08-15", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 22, "location_summary": "Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "St. Helena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241810" }, { "nct_id": "NCT02387216", "title": "A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "NSCLC", "Adenocarcinoma", "Heregulin" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2015-02-01", "completion_date": "2019-01-02", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02387216" }, { "nct_id": "NCT00994123", "title": "A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2010-02", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-08-22", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00994123" }, { "nct_id": "NCT00734305", "title": "Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "MM-121", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2008-07", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2016-09-01", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734305" }, { "nct_id": "NCT01447706", "title": "A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 223, "start_date": "2011-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 10, "location_summary": "Glendale, Arizona • Scottsdale, Arizona • Bakersfield, California + 7 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01447706" }, { "nct_id": "NCT01209195", "title": "A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,", "Primary Peritoneal Cancer or Endometrial Cancer", "Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer" ], "interventions": [ { "name": "MM-121", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merrimack Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2010-10", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209195" }, { "nct_id": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Pancreatic Cancer", "Lung Cancer", "Head and Neck Cancer", "Breast Cancer", "Kidney Cancer", "Colorectal Cancer", "Bladder Cancer", "Ovarian Cancer", "Sarcoma", "Gallbladder Cancer", "Bile Duct Cancer", "Esophageal Cancer", "Uterine Cancer", "Cholangiocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-09-29", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-09-06T02:17:54.333Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383210" } ] }